Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NITROFURANTOIN

All products: not a benefit

Other products in the same Health Canada class (J01X, J01XE) — coverage varies; not interchangeable

  • Micro crystals + nitrofurantoin mono (MacroBID): general benefit, Not a benefit
  • Fosfomycin tromethamine (Monurol): general benefit

Macrodantin · DIN 01997637 · 50mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.Discontinued 2010-07-07 · checked 2026-09-20
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Macrodantin · DIN 01997637 Manufacturer: Proctor & Gamble Pharmaceuticals Canada, Inc.; listing date 1996-10-01 Daily cost (source): $1.1708 Health Canada: Cancelled post market since 2010-07-07 · brand MACRODANTIN (50 MG) · ATC J01XE01 NITROFURANTOIN · form Capsule · route Oral · ingredients NITROFURANTOIN 50 MG · company Procter & gamble pharmaceuticals canada inc · schedule Prescription
Check this DIN again · Health Canada product record

Macrodantin: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14010 · Verify on the e-Formulary ↗ (DIN 01997637)

Source record
DIN 01997637: Macrodantin Raw flags: notABenefit=Y, sec3=Y Item: 083600013; group id 127; item number 0212; lccId None; manufacturer id PGP Source form: Cap; strength: 50mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01997637 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=14010
Interchangeable products
Jamp Nitrofurantoin · DIN 02495503 · $0.2927 Teva-Nitrofurantoin · DIN 02231015 · $0.2927
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Cancelled post market since 2010-07-07 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary class (08:36 Urinary Anti-Infectives) and how they are covered

Matched class: 08:36 Urinary Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: FOSFOMYCIN TROMETHAMINE Some products covered without a code (check the product listing): NITROFURANTOIN MONO/MICRO CRYSTALS 08:36 Urinary Anti-Infectives

NITROFURANTOIN MONO/MICRO CRYSTALS

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: 100mg · Cap

FOSFOMYCIN TROMETHAMINE

· 2 products · General benefit · strengths: · Sachet-3g Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 08:36
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:40 Miscellaneous Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
1 Indications NITROFURANTOIN (Nitrofurantoin tablets) is indicated for:  The treatment of pyelonephritis, pyelitis, and cystitis when due to susceptible organisms. NITROFURANTOIN is not for the treatment of associated renal cortical or perinephric abscesses, nor in prostatitis. To reduce the development of drug-resistant bacteria and maintain the effectiveness of NITROFURANTOIN and other antibacterial drugs, NITROFURANTOIN should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. 1.1 Pediatrics Pediatrics (< 1 month of age): Based on the data submitted and reviewed by Health Canada, the safety and efficacy of NITROFURANTOIN in pediatric patients has not been established; therefore, Health Canada has not authorized an indication for pediatric use. See 2 Contraindications. 1.2 Geriatrics Geriatrics (>65 years of age): Evidence from clinical st… https://pdf.hres.ca/dpd_pm/00080984.PDF PM date: 2025-07-03 Source product: NITROFURANTOIN; DIN 00312738; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For Macrodantin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026